Shares of Legend Biotech Co. (NASDAQ:LEGN – Get Free Report) have earned an average rating of “Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Thirteen investment analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $81.78.
LEGN has been the subject of a number of recent analyst reports. BMO Capital Markets reissued an “outperform” rating and issued a $90.00 target price on shares of Legend Biotech in a research report on Wednesday, July 3rd. Royal Bank of Canada reissued an “outperform” rating and set a $86.00 price objective on shares of Legend Biotech in a report on Friday. Truist Financial began coverage on shares of Legend Biotech in a research report on Monday, June 17th. They set a “buy” rating and a $88.00 price objective on the stock. Scotiabank lifted their target price on shares of Legend Biotech from $70.00 to $76.00 and gave the stock a “sector outperform” rating in a research report on Monday, August 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $73.00 target price on shares of Legend Biotech in a research note on Monday.
Read Our Latest Stock Analysis on Legend Biotech
Institutional Inflows and Outflows
Legend Biotech Price Performance
Shares of LEGN opened at $48.73 on Tuesday. Legend Biotech has a twelve month low of $38.60 and a twelve month high of $70.78. The company has a market capitalization of $8.88 billion, a P/E ratio of -37.48 and a beta of 0.11. The firm has a 50 day moving average of $53.97 and a 200 day moving average of $50.35. The company has a quick ratio of 4.78, a current ratio of 4.84 and a debt-to-equity ratio of 0.25.
Legend Biotech (NASDAQ:LEGN – Get Free Report) last posted its earnings results on Friday, August 9th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.49. The business had revenue of $186.50 million during the quarter, compared to analyst estimates of $125.25 million. Legend Biotech had a negative return on equity of 23.20% and a negative net margin of 62.50%. The company’s quarterly revenue was up 154.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.27) EPS. As a group, equities research analysts anticipate that Legend Biotech will post -1.46 earnings per share for the current fiscal year.
About Legend Biotech
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).
Featured Articles
- Five stocks we like better than Legend Biotech
- Business Services Stocks Investing
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Financial Services Stocks Investing
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.